1)Kezuka T, Usui Y, Yamakawa N et al:Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol 32:107-110, 2012
2)Jarius S, Ruprecht K, Kleiter I et al:MOG-IgG in NMO and related disorders:a multicenter study of 50 patients. Part 2:Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13:280, 2016
3)Ramanathan S, Mohammad S, Tantsis E et al:Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89:127-137, 2018
4)Lennon VA, Kryzer TJ, Pittock SJ et al:IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473-477, 2005
5)後関利明:抗MOG抗体陽性視神経炎—全国調査からわかったこと.神経眼科35:389-397,2018
6)Hacohen Y, Absoud M, Woodhall M et al:Autoantibody biomarkers in childhood-acquired demyelinating syndromes:results from a national surveillance cohort. J Neurol Neurosurg Psychiatry 85:456-461, 2014
7)Jarius S, Paul F, Aktas O et al:MOG encephalomyelitis:international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134, 2018
8)山口雄大・白井久美・住岡孝吉・他:和歌山県立医科大学附属病院での最近5年間の小児視神経炎の検討.臨眼73:341-346,2019
9)Hino-Fukuyo N, Haginoya K, Nakashima I et al:Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Brain Dev 37:849-852, 2015
10)Mariotto S, Gajofatto A, Batzu L et al:Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 93:e1867-e1872, 2019
11)Sato DK, Callegaro D, de Haidar Jorge FM et al:Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol 76:305-309, 2014
12)毛塚剛司:抗MOG抗体陽性視神経炎.臨眼71:1676-1681,2017
13)Wynford-Thomas R, Jacob A, Tomassini V:Neurological update:MOG antibody disease. J Neurol 266:1280-1286, 2019